Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of AZD2816 (Beta Variant Vaccine) for COVID-19
NCT04973449Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Jun 2021
- Primary completion
- Feb 2022
- Modality
- Viral Vector Vaccines
- Countries
- 4
01
Overview
A Phase 3 trial of ChAdOx1 nCoV-19 in coronavirus disease 2019 (COVID-19), sponsored by AstraZeneca. Started Jun 2021; status: completed.
02
Drugs
ChAdOx1 nCoV-19
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04973449.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04973449.